PD-L1

4 · 20 / page

Ask MedXY AI

Latest news

Tag

newsCost-Effectivenessimmunotherapy

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY|Aug 11, 2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

Gastroenterologyhepatocellular carcinoma

PD-L1

Latest news

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

Checkpoint Inhibition Is Reshaping Pediatric Lymphoma Care, Led by Breakthroughs in Hodgkin Lymphoma and Expanding into PD-L1–Positive Non-Hodgkin Subtypes

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression